• Profile
Close

Denosumab improves glomerular filtration rate in osteoporotic patients with normal kidney function by lowering serum phosphorus

Journal of Bone and Mineral Research Aug 17, 2019

Miyaoka D, Inaba M, Imanishi Y, et al. - In this investigation, researchers evaluated denosumab for its renoprotective impact and how denosumab-induced reduction in serum phosphorus (Pi) impacts osteoporotic patients. During the study period (24 months), 73 osteoporotic patients without obvious proteinuria in dipstick test results were treated with denosumab (60 mg) every 6 months. Investigators found that the reduction in serum Pi due to phosphorus load reduction from bone induced by denosumab is a determinant for an increase in estimated glomerular filtration rate based on serum cystatin C. In cases of osteoporosis, including non-chronic kidney disease patients, early introduction of bone anti-resorptive therapy may retain glomerular filtration.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay